ERS Genomics: Foundational CRISPR/Cas9 gene editing patent g

DUBLIN, Jan. 5, 2023 /PRNewswire/ -- ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9 in humans, animals

Related Keywords

California , United States , Vienna , Wien , Austria , Canada , Dublin , Ireland , Canadian , Kostenloser Wertpapierhandel , Emmanuelle Charpentier , Michael Arciero , Dara Odonnell , Jennifer Doudna , University Of California , Corporate Development , Vp Ip Commercial Development , University Of Vienna , Nobel Laureate , Intellectual Property , Nobel Prize , Darao Donnell , Genomics , Foundational , Rispr , Cas9 , Gene , Editing , Patent , Granted ,